Summary: Classical iron deficiency (ID) is not a challenge for the laboratory and physicians. The diagno-
Introduction
Worldwide anaemia remains an enormous problem as more than 1 billion people suffer from this condition, the most important causes being iron deficiency, chronic inflammatory disorders and hereditary disorders of haemoglobin synthesis. Red cell production is a process regulated in the proliferation and the maturation pool of the bone marrow. In the proliferation pool the red cell progenitors require stimuli from cytokines for survival and proliferation. Every erythroid precursor cell needs at least stimulation of 10 erythropoietin molecules (1) . A large quantitity of iron is needed in the maturation pool to make about 30 mL of red blood cells per day.
The pathogenesis of anaemia that accompanies infection, inflammation, and cancer, commonly termed anaemia of chronic disorders (ACD) (2) and the anaemia of endstage renal failure (3) are attributed to a blunted response of erythroid precursor cells to erythropoietin or a reduced synthesis of the cytokine ( Figure 1) . A reduced number of red cells arise from the marrow red cell precursor pool, however if enough iron is available, every precursor cell which enters the maturation pool will have a normal red cell haemoglobinization (4) . In the complete blood cell count a mild normocytic normochromic anaemia is measured.
Patients with ACD present the following clinical laboratory results (Table I) :
-Low serum iron and low transferrin saturation resulting from retention of iron by reticuloendothelial macrophages and reduced intestinal iron absorption.
-Normal ferritin concentration in their early course elevated values in the later stages because much iron is retained in macrophages.
-Reduced reticulocyte count because of hypoproliferative erythropoiesis.
sis is associated with microcytic hypochromic anemia and low serum ferritin. Anemia that accompanies infection, inflammation, and cancer, commonly termed anemia of chronic disorders (ACD) has apparently normal or increased iron stores. However, 20% of these patients have iron-restricted erythropoiesis (functional ID), an imbalance between iron requirements of the erythroid marrow and the actual iron supply. Functional ID leads to a reduction of red cell hemoglobinization, which causes hypochromic microcytic anemia. The early diagnosis of functional ID is based on the measurement of heamoglobin content of reticulocytes. This index can be estimated measuring the CHr with the Bayer Advia analyzer or the Ret-Y, using the Sysmex XE analyzer series. A CHr < 28 pg or a Ret-Y < 1630 are sensitive indicators of functional ID. For the assessment of iron status and the detection of advancing iron deficiency in patients with ID, ACD and the combined state of functional ID/ACD a diagnostic plot was developed. The plot indicates the correlation between the ratio sTfR/log ferritin (ferritin index), a marker of iron supply for erythropoiesis, and the CHr or Ret-Y. The diagnostic plot shows a good selectivity to assess the iron status of disease specific anemias like classical ID, endstage renal failure, cancer related anemia and anemia of infection and inflammation. Therapeutic implications of the diagnostic plot are to differentiate patients who should be administered with oral iron, with r-HuEPO or a combination of r-HuEPO and iron. The therapy can be monitored using the CHr, the Ret-Y, the sTfR or the diagnostic plot. An increase of CHr > 1 pg, of sTfR > 20% or an upward movement of the patient data point in the diagnostic plot indicates response to iron or r-HuEPO.
Iron deficiency anaemia (IDA) results from a reduced iron supply for erythropoiesis in the maturation pool. Iron restricted erythropoiesis (IRE) can result from classical iron deficiency, the combined state of IRE with the ACD and in functional iron deficiency ( Figure 2) . The most important classical iron deficiency (ID) is not a challenge for the laboratory and physicians. The diagnosis is associated with microcytic hypochromic anaemia and low serum ferritin because of depleted body iron stores (4) . About 20% of patients with ACD have iron-restricted erythropoiesis nevertheless they have repleted body iron stores (6) . Anaemia results from impaired iron recycling. Functional iron deficiency (FID) is an imbalance between iron requirements of the erythroid marrow and the actual iron supply (7) . FID is common in r-HuEPO treatment without iron supplementation (8) . Functional ID like IRE leads to a reduction of red cell haemoglobinization, which causes hypochromic microcytic anaemia. The expressions IRE and FID are used as synonyms.
Laboratory tests for iron status include biochemical markers and haematological indices ( Table II) . The conventional biochemical markers include serum iron, transferrin/total iron-binding capacity, transferrin saturation and ferritin. Although widely used, these parameters are influenced by the acute phase response (APR) which complicates clinical interpretation of the test results. Ferritin is an acute phase reactant. The serum soluble transferrin receptor (sTfR) assay is yet another promising tool for the diagnosis of iron depletion (9) . Calculation of the ratio sTfR/log ferritin (sTfR/log ferritin or sTfR-F index) is a way of combining sTfR and ferritin results (10) . Besides the complete blood count new haematological indices which have gained merit in the assessment of iron status include the reticulocyte haemoglobin content measured as CHr or RET-Y (11, 12) . The objectives of our studies were threefold: (1) to compare the biochemical markers of iron status with the haematological indices for the detection of IRE, especially in patients with APR, (2) to develop a diagnostic plot combining haematological indices with biochemical markers as a tool for identification of different phases of advancing ID in anemic patients with and without APR, and (3) to evaluate the diagnostic plot for monitoring IRE in oral iron supplementation and FID in r-HuEPO treatment.
Comparison of biochemical markers of iron status with haematological indices for the detection of iron restricted erythropoiesis
Red cell haemoglobinisation, especially the haemoglobin content of reticulocytes provides direct evaluation of the bone marrow activity reflecting the balance between iron and erythropoiesis. Modern haematology analysers capable of identifying small subpopulations of erythrocytes within the total RBC population offer appropriate tools. The haemoglobin content of reticulocytes can be estimated measuring the CHr with the Bayer Advia analyzer or the Ret-Y, using the Sysmex XE analyzer series. We evaluated a reference range for CHr of 28 -35 pg and for Ret-Y of 1630-1860 arbitrary units corresponding to a haemoglobin content (Ret-H e ) of 28.2-36.4 pg (6, 13).
The APR has a strong influence on the iron supply for erythropoiesis. Therefore the biochemical markers of iron status were compared with haematological indices in groups of anaemic patients with and without APR. The C-reactive protein (CRP) assay was used as a marker of inflammation, all patients with a CRP level greater than 5 mg/L being considered to have an inflammatory disorder. The sTfR level was measured using the Dade assay.
Using the CHr and Ret-Y < 28 pg as a gold standard for IRE the sTfR/log ferritin was the most accurate marker for biochemical identification of IRE. However, as shown from the area under curve from the ROC plots, the accuracy of the sTfR/log ferritin in patients with APR was insufficient (Figure 3) . From these studies we found that patients with a sTfR/log ferritin higher than 1.5 have iron depleted stores while patients with an index less than 1.5 have stores which are iron replete. However, in patients with elevated CRP levels, the separation point is 0.8 since ferritin is an acute phase protein and is elevated in inflammato- Sensitivity, % Sensitivity, % ry disorders independently of the body iron stores. As a result the sTfR/log ferritin is increased and the decision point is moved to a ratio of 0.8 (6).
Development of a diagnostic plot for identification of different phases of advancing iron deficiency
The rationale behind the diagnostic plot was to combine the best marker of iron supply for erythropoiesis with the CHr or RET-Y (Ret-H e ) as indicators of bone marrow iron demand (Figure 4 ). Patients with a CHr level greater than 28 pg or RET-H e greater than 28.2 pg (normal haemoglobinisation of reticulocytes) have not IRE or FID whereas those with CHr less than 28 pg or Ret-H e less than 28.2 pg (reduced haemoglobinisation of reticulocytes) have IRE or FID. It is also important to know whether or not an inflammatory disorder coexists. For patients without inflammation, the ferritin index separating iron depleted from an iron replete state is 1.5 as previously stated. On this basis the diagnostic plot is divided into four quadrants. Patient data points in quadrant 1 indicate replete iron stores and normal red cell hemoglobinisation. In this quadrant are located patients with cancer-related anaemia (CRA), ACD, and end stage renal failure patients without IRE or FID. In quadrant 2 there may be reduced iron supply but erythropoiesis is not yet iron deficient and haemoglobinisation of the red cells remains normal. Included in this quadrant are non-anaemic patients with latent iron deficiency, patients with iron deficiency shortly after commencing oral iron therapy, patients with hyperproliferative erythropoiesis due to acute haemorrhage, haemolysis and in the third trimester of pregnancy with increased sTfR but no IRE. Points in quadrant 3 suggest reduced iron supply as being the cause of IRE attributable to depleted iron stores as typically occurs in classical IDA. Data points in quadrant 4 occur in iron replete patients with the combined state of IRE/ACD who have anaemia accompanying infection or chronic inflammation and in the APR that accompanies cancer-related anaemia. Patients with b-thalassaemia trait have also points in quadrant 4. The diagnostic plot shows a good selectivity to assess the iron status of disease specific anaemias like classical ID, endstage renal failure, cancer related anaemia and anaemia of infection and inflammation (6) .
Therapeutic implications of the diagnostic plot
Therapeutic implications of the diagnostic plot are to differentiate patients who should be administered with oral iron, with r-HuEPO or a combination of rHuEPO and iron ( Figure 5 ). Anaemic patients with data points in quadrants 2 and 3 are recommended for oral iron supplementation to the clinician. Usually in adequate oral iron supplementation patients respond with movement of data point from quadrant 3 into quadrant 2 within 10 days and into quadrant 1 after 4 weeks.
Anaemic patients with data points in quadrants 1 and 4 are recommended for r-HuEPO therapy. Patients with data points in quadrant 4 need intravenous iron supplementation with the first r-HuEPO dosage, patients with data points in quadrant 1 should be treated primarily only with r-HuEPO. The response of erythropoiesis to r-HuEPO is indicated by movement of the data points within the plot ( Figure 6 ). An increase in CHr within a quadrant indicates sufficient iron supply to erythropoiesis, the decrease is an indication of FID. A movement of the data points into quadrants 2 and 3 is a sign of storage iron deficiency and a response to r-HuEPO.
In conclusion, biochemical markers of ID are only of value in diagnosing iron-restricted erythropoiesis in patients without APR. The combination reticulocyte indices CHr or RET-Y (RET-H e ) with the sTfR-F index in a diagnostic plot offers an attractive tool for identification of different phases of ID (14) and therapeutic monitoring of IRE. 
